))
iRhythm closes offering worth more than $660M; FDA accepts Onward BCI into advisory program
Manage episode 406066110 series 3481361
Content provided by Fast Five by MassDevice. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Fast Five by MassDevice or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, March 12, 2024. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Boston Scientific reported positive results for the agent drug-coated balloon study. Fast Five hosts Danielle Kirsh and Sean Whooley talk about the technology and the data points that stick out. Medtronic is highlighting the global performance of its MiniMed 780G automated insulin delivery system. Hear about what the new data highlights and some of the most compelling data the company highlighted. The FDA has cleared Pulse Biosciences' pulsed field ablation electrode technology. Whooley talks about what the PFA electrode technology does and some of the optimism that executives have. Onward was accepted into an FDA advisory program. The Fast Five hosts talk about the technology that got them into the advisory program and what the acceptance means. iRhythm closed an offering worth more than $660 million. Learn more about what is included in this offering and what the company plans to use the proceeds for.
…
continue reading
161 episodes
Share
